Core Viewpoint - A class action lawsuit has been filed against Paysafe Limited due to allegations of securities fraud and unlawful business practices, following disappointing financial results and a significant stock price drop [1]. Financial Performance - Paysafe reported third-quarter 2025 revenue of $433.8 million, missing consensus estimates by $5.8 million [1]. - The company experienced a net loss of $87.7 million, a substantial increase from a net loss of $12.98 million in the same period the previous year [1]. - Full-year 2025 expected revenue has been revised down to $17 million at the midpoint, with adjusted EPS projected at $0.50 [1]. Management Commentary - CEO Bruce Lowthers indicated that a last-minute client shutdown led to several million-dollar write-downs in Q3 [1]. - The company is facing challenges in a lower-tier market, particularly with high-risk Merchant Category Codes (MCC), which are difficult for banks to underwrite [1]. - Lowthers acknowledged ongoing difficulties with certain MCC codes and the company's efforts to navigate these challenges [1]. Stock Market Reaction - Following the announcement of the financial results, Paysafe's stock price fell by $2.80 per share, or 27.6%, closing at $7.36 per share on November 13, 2025 [1].

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ramaco Resources, Inc. of Class Action Lawsuit and Upcoming Deadlines - METC [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ramaco Resources, Inc. ("Ramaco" or the "Company") (NASDAQ: METC). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-free, ...

Core Viewpoint - A class action lawsuit has been filed against PomDoctor Ltd. for alleged securities fraud and unlawful business practices, with a significant drop in share price following a promotional scheme [1] Group 1: Class Action Lawsuit Details - The lawsuit is focused on whether PomDoctor and its officers engaged in securities fraud [1] - Investors have until April 6, 2026, to apply as Lead Plaintiff if they purchased PomDoctor securities during the Class Period [1] Group 2: Share Price Movement - PomDoctor's share price increased from $4.00 to an all-time high of $6.09 before crashing by approximately 91% to $0.50 on December 10, 2025 [1] - The price surge occurred without any fundamental news from the company, raising concerns about the legitimacy of the increase [1] Group 3: Allegations of Fraud - Investigations revealed that PomDoctor allegedly used social media for a "pump and dump" scheme, misleading investors through impersonation and baseless claims [1] - The promotional activities created a buying frenzy among retail investors, leading to significant financial losses [1]

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in China Liberal Education Holdings Limited of Class Action Lawsuit and Upcoming Deadlines - CLEUF [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against China Liberal Education Holdings Limited ("CLEU" or the "Company") (OTCMKTS: CLEUF). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581 ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4- ...

Core Viewpoint - A securities class action lawsuit has been filed against Varonis Systems, Inc. and its executives, with a lead plaintiff deadline approaching on March 9, 2026, focusing on allegations of concealed issues in the company's transition to a Software-as-a-Service (SaaS) model [1][4]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Varonis executives failed to disclose significant renewal challenges in its Federal vertical and legacy on-premises business while promoting a smooth transition to SaaS [2][5]. - Following a disclosure on October 28, 2025, regarding difficulties in converting existing customers to the SaaS model, Varonis reported a 63.9% year-over-year decline in term license revenue and reduced its Annual Recurring Revenue (ARR) outlook, leading to a 48% drop in stock price, equating to a loss of approximately $3.8 billion in market value [3][9]. Group 2: Company Performance and Market Reaction - The lawsuit highlights a discrepancy between Varonis's optimistic statements about its SaaS transition and the actual struggles faced in its Federal renewal cycle and on-premises subscription business [5][9]. - After the Q3 performance miss, Varonis significantly reduced its Q4 revenue and full-year ARR guidance, which contributed to the sharp decline in stock value from $63.00 to $32.34 in a single day [9].

Core Viewpoint - The lawsuit against Plug Power, Inc. alleges that the company materially overstated the likelihood of receiving funds from a Department of Energy (DOE) loan and that it would pivot to less ambitious projects, impacting investor confidence and share prices [4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Plug Power securities between January 17, 2025, and November 13, 2025 [4]. - Investors who suffered losses have until April 3, 2026, to request lead plaintiff appointment, which is crucial for overseeing the litigation [2]. - The lawsuit claims that Plug Power misrepresented the availability of DOE loan funds and the construction of hydrogen production facilities [4]. Group 2: Company Developments - On October 7, 2025, Plug Power announced the resignation of CEO Andrew Marsh and President Sanjay Shrestha, leading to a 6.3% decline in share price from $4.13 to $3.87 [5]. - Following an agreement for the immediate exercise of outstanding warrants, Plug Power raised approximately $370 million, but the share price fell by 5.4% from $3.87 to $3.66 [6]. - On November 10, 2025, the company reported financial results and announced a significant pivot by suspending activities under the DOE loan program, causing a 3.4% drop in share price from $2.65 to $2.56 [7]. - On November 13, 2025, it was reported that Plug Power confirmed the suspension of plans to construct hydrogen facilities, resulting in a 17.6% decline in share price from $2.73 to $2.25 [9].

SAN FRANCISCO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Klarna Group plc (NYSE: KLAR) of the upcoming February 20, 2026, lead plaintiff deadline in a pending securities class action. The firm is actively investigating the lawsuit’s claims of alleged misstatements in Klarna’s September 2025 Initial Public Offering (IPO) documents. CLICK HERE TO SUBMIT YOUR KLARNA LOSSES Investors who purchased Klarna (KLAR) shares pursuant to the company’s ...

Core Viewpoint - A class action securities lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud affecting investors between September 2, 2025, and October 31, 2025 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2] - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [2] - As a result, the positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses in Picard Medical during the specified timeframe have until April 3, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Plug Power Inc. for alleged securities fraud affecting investors between January 17, 2025, and November 13, 2025 [1] Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the availability of funds from the U.S. Department of Energy's Loan Program, overstating the likelihood that these funds would be accessible to Plug Power [2] - It is claimed that Plug Power was likely to shift towards less ambitious projects with lower commercial potential, contradicting public statements made by the company [2] - The lawsuit asserts that the company's public statements were materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses in Plug Power during the specified timeframe have until April 3, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]